ScoreWhy is NextCell Pharma AB ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -57.37%, its profits have fallen by -6.5%
3
Underperformed the market in the last 1 year
- Even though the market (OMX Stockholm 30) has generated returns of 10.97% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -57.37% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is NextCell Pharma AB for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
NextCell Pharma AB
-57.37%
-0.10
110.58%
OMX Stockholm 30
10.97%
0.59
18.59%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
22.47%
EBIT Growth (5y)
-134.70%
EBIT to Interest (avg)
-35.18
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.51
Sales to Capital Employed (avg)
0.18
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.44
EV to EBIT
-2.05
EV to EBITDA
-2.19
EV to Capital Employed
3.43
EV to Sales
8.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-166.83%
ROE (Latest)
-96.77%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
NET PROFIT(HY)
Higher at SEK -18.9 MM
RAW MATERIAL COST(Y)
Fallen by -58.97% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 85.85 times
EPS(Q)
Highest at SEK -0.08
-1What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at 0 %
Here's what is working for NextCell Pharma AB
Net Profit
Higher at SEK -18.9 MM
than preceding 12 month period ended Aug 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
EPS
Highest at SEK -0.08
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (SEK)
Inventory Turnover Ratio
Highest at 85.85 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -58.97% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for NextCell Pharma AB
Debt-Equity Ratio
Highest at 0 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
